Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-41,449
Closed -$609K 1270
2025
Q3
$609K Buy
41,449
+14,844
+56% +$151K 0.02% 447
2025
Q2
$261K Sell
26,605
-2,641
-9% -$21.9K 0.01% 766
2025
Q1
$213K Buy
29,246
+11,076
+61% +$96.8K 0.01% 877
2024
Q4
$142K Sell
18,170
-7,673
-30% -$63.2K 0.01% 1049
2024
Q3
$191K Sell
25,843
-1,257
-5% -$10.6K 0.01% 1060
2024
Q2
$217K Sell
27,100
-44,640
-62% -$399K 0.01% 939
2024
Q1
$835K Sell
71,740
-1,401
-2% -$15.5K 0.03% 399
2023
Q4
$817K Buy
73,141
+9,116
+14% +$83.8K 0.04% 371
2023
Q3
$989K Sell
64,025
-8,548
-12% -$143K 0.05% 285
2023
Q2
$1.38M Buy
72,573
+14,497
+25% +$255K 0.07% 235
2023
Q1
$884K Buy
+58,076
New +$757K 0.05% 329

Other funds holding ETNB

Profund Advisors's ETNB Position: Q4 2025 in Review

Profund Advisors sold out of 89bio (ETNB) in Q4 2025, closing a stake of 41,449 shares — an estimated $609K sold.

Profund Advisors first reported a position in ETNB in Q1 2023 and held it in 11 quarters. The position peaked at $1.38M in Q2 2023. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.

  • Profund Advisors reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
  • Profund Advisors sold 41,449 89bio shares in Q4 2025, an estimated $609K.
  • Profund Advisors first reported a position in 89bio in Q1 2023 and held it in 11 quarters.
  • Profund Advisors's 89bio position peaked at $1.38M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.

Based on Profund Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.